CVE-2021-4479: Dräger Atlan A350 Denial of Service via Medibus Interface

Technical summary

CVE-2021-4479 is an improper input validation flaw in the Medibus interface implementation of affected Dräger Atlan A350 units. The vulnerability stems from insufficient sanitization of incoming network data (CWE-1286: Improper Validation of Specified Quantity in Input). Non-Medibus-compliant packets are not properly rejected or buffered; instead, they accumulate and consume processor resources. The attack is not instantaneous—it requires sustained transmission of crafted packets over hours to produce noticeable clinical impact. Network-based delivery via the Medibus protocol stack means the attacker needs network access to the device but not direct physical interaction or authentication credentials.

Business impact

In hospital environments where Atlan A350 devices monitor critical patients, degraded or delayed waveform display and data transmission loss directly threaten patient safety and clinical workflow. Clinicians rely on real-time airway pressure and vital sign curves for ventilation adjustments; display lag or data gaps introduce diagnostic uncertainty. Affected facilities may face increased alarm fatigue, need for manual verification of readings, and potential escalation of care incidents if device degradation goes undetected during high-acuity shifts. Device replacement or emergency firmware patching would disrupt monitoring continuity.

Affected systems

Dräger Atlan A350 patient monitors running firmware versions 1.00 and 1.01 are confirmed vulnerable. The vendor has not provided specific product revision numbers or related product lines confirmed as affected. Organizations should consult the official Dräger security advisory to determine whether other versions, regional variants, or connected integrated systems are in scope.

Exploitability

Exploitation requires network access to the Medibus interface—typically available only from systems already on the hospital network (e.g., central monitoring stations, gateways, or compromised clinical workstations). The attack vector is Network, but Attack Complexity is High, suggesting the attacker must satisfy specific protocol conditions or timing to trigger sustained degradation. The CVSS score of 4.0 (Medium) reflects that while the availability impact is real, the narrow scope (Scope Changed but only Availability affected), high barrier to access, and lack of authentication bypass mean opportunistic exploitation is unlikely. No public exploit code or active exploitation has been reported.

Remediation

Dräger has issued firmware updates addressing improper input handling in the Medibus interface. Organizations must verify the availability of patched firmware versions from Dräger and coordinate updates with their biomedical engineering and clinical teams to minimize monitoring downtime. Interim mitigations include network segmentation to restrict access to the Medibus interface and monitoring for unusual traffic patterns indicative of an exploitation attempt.

Patch guidance

Contact Dräger support to obtain and deploy the latest firmware for Atlan A350 units. Verify the new firmware version against Dräger's official advisory to confirm it addresses CVE-2021-4479. Schedule updates during low-acuity periods or with backup monitoring in place to maintain patient safety. Test patched devices in a non-clinical environment if possible before production deployment. Document the patching timeline and affected device serial numbers for compliance and audit purposes.

Detection guidance

Monitor Medibus network traffic for abnormally formatted or non-compliant packets targeting Atlan A350 devices, or look for repeated connection attempts from unexpected sources. Clinical engineering teams should watch for early-warning signs of degradation: occasional display lag or missed data points that gradually worsen over hours. Log analysis of device network interfaces may reveal sustained packet floods or protocol violations. Establish baseline performance metrics for Atlan A350 displays and alert on deviations in curve update frequency or data transmission latency.

Why prioritize this

Although the CVSS score is moderate (4.0), the clinical context elevates prioritization. Patient monitoring devices are safety-critical; any degradation in real-time data availability or display accuracy can influence clinical decisions. The attack is feasible only from the hospital network, reducing external threat likelihood, but insider or compromised-system scenarios are credible. Facilities with Atlan A350 units should prioritize patching over non-critical systems, but the availability impact and clinical dependency justify it above purely informational vulnerabilities.

Risk score, explained

CVSS 4.0 (Medium) reflects a network-accessible availability flaw with high attack complexity and limited scope (only the target device). No confidentiality or integrity exposure means the attacker cannot steal data or falsify readings—only degrade performance. The Scope Changed designation acknowledges that a single compromised Medibus network can potentially affect multiple connected devices or systems, but the primary impact remains denial of service to the targeted device. Organizations with robust network segmentation and monitoring may lower their operational risk significantly; those with flat clinical networks face higher practical exposure.

Frequently asked questions